← Back to headlines
Propanc Biopharma Reports Promising Preclinical Pancreatic Cancer Data
Propanc Biopharma announced compelling preclinical results for its drug candidate PRP, demonstrating over 90% tumor growth inhibition and a significant survival benefit in pancreatic cancer models.
27 Aug, 12:30 — 27 Aug, 12:30
